Data as of Dec 19
| -0.42 / -0.58%|
The 32 analysts offering 12-month price forecasts for AstraZeneca have a median target of 71.75, with a high estimate of 91.23 and a low estimate of 46.94. The median estimate represents a +0.08% increase from the last price of 71.69.
The current consensus among 32 polled investment analysts is to Hold stock in AstraZeneca. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.